DRUG AND THERAPYBULLETIN
HIMACHALPRADESHSTATEPHARMACYCOUNCIL
DRUGINFORMATIONCENTER
LAUREATE INSTITUTE OF PHARMACY, KATHOG, DISTT. KANGRA, HP - 177101
Toll Free : 18001210443 |Phone: 9218428042/9459220253|E-mail: [email protected]/[email protected]
Toll Free: 18001210443
Issue 18|Volume 3|March 2019
ContentsDrug Updates
Pharma News
Pharmacist Result
Local News
Noble Prize in Physiology or Medicine, 2018
1
DRUG AND THERAPY BULLETIN
Content
EDITORIAL
AdvisoryBoard
Dr. Navneet Marwah, Mr. Sanjeev Pandit, Dr. Manoj Kumar, Dr. Ranjit Singh, Prof. CPS Verma,
Dr. Poonam Sandhu, Dr. Rajender Guleria,Mr. Arvind Kumar,Mr. Bihari Lal Gupta,Mr, Hemant Sharma,
Mr.RakeshChandel,Mr.PraveenUpadhya,Mr.KamashwarChauhan,Mr.LokeshKumar,Mr.VishalKumar,
Mr.Y.S.Chandel,Mr.BirbalSharma,Mr.ManojKumar,Mr.YogeshVerma,Mr.SurenderNadda,Dr.Parshuram
Patron
Mr.GopalKrishanSharmaandDr.RanSingh
Editor-in-Chief
Dr.KamleshNaikandDr.M.S.Ashawat
Co-Editors
Dr.VinayPanditandMr.AnkushSharma
Drug Updates
FDA:UloricCVdeathBBW...........................................................................................................................................................3
EsperoctforHemophiliaA...........................................................................................................................................................3
Keytruda:AdjuvantforMelanoma............................................................................................................................................3
Egatenforfascioliasis............................................................................................................................................................................................3
Darzalex:Newsplitdosingregimen........................................................................................................................................3
CabliviforaTTP.................................................................................................................................................................................4
Pharma News
Governmentbrings42non-scheduledcancerdrugsunderpricecontrol.................................................................4
FDAadvancesnewproposedregulationtomakesurethatsunscreensaresafeandeffective.....................4
DRUG INFORMATION CENTER HIMACHAL PRADESH STATE PHARMACY COUNCIL
Laureate Institute of Pharmacy, Kathog, Distt Kangra, HP - 177101
Toll Free : 18001210443 |Phone: 9218428042/9459220253|E-mail: [email protected]/[email protected]
2
Content (Continued)SCexemptspainkillerSaridonfromthebannedlistinIndia........................................................................................5
MinistryofAYUSHintroducednewCentralSectorschemeforpromotingPharmacovigilanceofAYUSH
Drugs.....................................................................................................................................................................................................5
FDAauthorizes�irstinteroperableinsulinpumpintendedtoallowpatientstocustomizetreatment
throughtheirindividualdiabetesmanagementdevices................................................................................................6
PharmacistResult
PharmacistResult..................................................................................................................................................7,8,9,10,11,12
LocalNews
LocalNews................................................................................................................................................................................14,15
DRUG INFORMATION CENTER HIMACHAL PRADESH STATE PHARMACY COUNCIL
Laureate Institute of Pharmacy, Kathog, Distt Kangra, HP - 177101
Toll Free : 18001210443 |Phone: 9218428042/9459220253|E-mail: [email protected]/[email protected]
NoblePrizeinPhysiologyorMedicine,2018
NoblePrizeinPhysiologyorMedicine,2018..............................................................................................................13,14
3
Drug Updates
FDA:UloricCVdeathBBW
OnFebruary21,2019,theUSFDAhasconcluded
thatthereisanincreasedriskofdeathwithUloric
(febuxostat) oral tablets compared with
allopurinol, another gout drug. In the CARE
clinical trial, therewas a signi�icant increase in
cardiovascular(CV)deathandoverallmortalityin
patientstreatedwithUloriccomparedwiththose
treatedwithallopurinol.Asaresult,theFDAhas
required an update to the Uloric prescribing
informationtorequireablackboxwarning(BBW)
andanewpatientmedicationguide.Inaddition,
the approved use of Uloric is being limited to
certainpatientswhoarenottreatedeffectivelyor
experienceseveresideeffectswithallopurinol.
P re s c r i b i n g i n f o rma t i on c an b e f o und a t :
http://general.takedapharm.com/content/�ile/pi.pdf ?�
iletypecode=ULORICPI.
DRUG INFORMATION CENTER HIMACHAL PRADESH STATE PHARMACY COUNCIL
Laureate Institute of Pharmacy, Kathog, Distt Kangra, HP - 177101
Toll Free : 18001210443 |Phone: 9218428042/9459220253|E-mail: [email protected]/[email protected]
EsperoctforHemophiliaA
On February 19, 2019, the US FDA approved
Esperoct(R) (antihemophilic factor (recombinant),
glycopegylated-exei) IV injection for the treatment of
adult and pediatric patients with hemophilia A
(congenital factor VIII deficiency) for routine
prophylaxis to reduce the frequency of bleeding
episodes, on-demand treatment and control of
bleeding episodes, and perioperative management
of bleeding. Approval was based on a clinical trial in
which Esperoct provided effective routine prophylaxis
in patients with severe hemophilia A and showed
efficacy in the treatment of bleeding episodes and
perioperative management. Esperoct has an
extended half-life in adult and pediatric patients
compared with standard factor VIII products.
P r e s c r i b i n g i n f o r m a t i o n c a n b e f o u n d
at:https://www.fda.gov/downloads/BiologicsBloodVac
cines/UCM631602.pdf.
On February 19, 2019, the US FDA approved
Keytruda(R)(pembrolizumab)IVinjectionforthe
adjuvant treatment of patients with melanoma
with involvement of lymph node(s) following
complete resection. Keytruda, which is already
approved for 3 other melanoma indications,
demonstrated signi�icant recurrence-free
surviva l compared with p lacebo in the
EORTC1325/KEYNOTE-054trial.
Prescribinginformationcanbefoundat:
https://www.accessdata.fda.gov/drugsatfda_docs/labe
l/2019/125514s040lbl.pdf.
Keytruda:AdjuvantforMelanoma
Egatenforfascioliasis
On February 13, 2019, the US FDA approved
Egaten(R)(triclabendazole)oraltabletstoforthe
treatment of fascioliasis in adult and pediatric
patients6yearsofageorolder.Egatenistheonly
FDA-approved drug and the on ly drug
recommended by World Health Organization
(WHO)forfascioliasis,commonlyknownasliver
�lukeinfestation.
Prescribinginformationcanbefoundat:
https://www.accessdata.fda.gov/drugsatfda_docs/labe
l/2019/208711s000lbl.pdf.
4
DRUG INFORMATION CENTER HIMACHAL PRADESH STATE PHARMACY COUNCIL
Laureate Institute of Pharmacy, Kathog, Distt Kangra, HP - 177101
Toll Free : 18001210443 |Phone: 9218428042/9459220253|E-mail: [email protected]/[email protected]
Darzalex:Newsplitdosingregimen
On February 12, 2019, the US FDA approved a
s p l i t - do s i n g re g imen fo r Da r z a l ex (R )
(daratumumab) IV injection for patients with
multiplemyeloma.Thisnewdosingregimenfor
Darzalex, which provides an option to split the
�irstdoseover2consecutivedays,wasapproved
basedondatafromthePhase1bEQUULEUStrial
in which daratumumab concentrations were
similarafterweeklydosingwhengivenasasingle
�irstinfusionorsplitinfusion.
Prescribinginformationcanbefoundat:
https://www.accessdata.fda.gov/drugsatfda_docs/labe
l/2019/761036s016lbl.pdf.
CabliviforaTTP
On February 6, 2019, the US FDA approved
Cablivi(R) (caplacizumab-yhdp) IV or subQ
injection indicated for the treatment of adult
p a t i e n t s w i t h a c q u i r e d t h r om b o t i c
t h rombocy topen i c purpura ( aTTP) , i n
combination with plasma exchange and
immunosuppressivetherapy.Cablivi,whichisthe
�irst targeted treatment that inhibits blood clot
formation,demonstratedef�icacyinaclinicaltrial
inwhichplateletcountsimprovedmorequicklyin
patients treated with caplacizumab-yhdp
comparedwiththosetreatedwithplacebo.
P re s c r i b i n g i n f o rma t i o n c an b e f o und a t :
https://www.accessdata.fda.gov/drugsatfda_docs/labe
l/2019/761112s000lbl.pdf.
Ref:www.micromedexsolutions.com
Pharma News
The government said it has brought 42 non-
scheduledanti-cancerdrugsunderpricecontrol,
cappingtrademarginat30percent,whichwould
reducetheirretailpricesbyupto85percent.The
National Pharmaceutical Pricing Authority
(NPPA) has invoked extraordinary powers in
publicinterest,underPara19oftheDrugs(Prices
Control)Order,2013tobring42non-scheduled
anti-cancer drugs under price control through
trade margin rationalisation, an of�icial release
said.
"Invoking paragraph 19 of DPCO, 2013, the
governmentherebyputsacapontrademarginof
30percentanddirectsmanufacturersto�ixtheir
retailpricebasedonpriceat�irstpointofsaleof
product... of the non-scheduled formulations
containinganyofthe42drugs,"theDepartmentof
Pharmaceuticals (DOP)said inanoti�ication.As
per data availablewith NPPA, theMRP for 105
brandswillbereducedupto85percententailing
minimumsavingofRs105croretoconsumers,it
added.Currently,57anti-cancerdrugsareunder
pricecontrolasscheduledformulations.Now42
non-scheduledanti-cancermedicineshavebeen
selectedforpriceregulationbyrestrictingtrade
marginon the sellingprice (MRP)up to30per
cent,thenoti�icationsaid.
Ref:www.health.economictimes.indiatimes.com
Governmentbrings42non-scheduledcancer
drugsunderpricecontrol
FDAadvancesnewproposedregulationtomakesurethatsunscreensaresafeandeffective
TheU.S.FoodandDrugAdministration issueda
5
DRUG INFORMATION CENTER HIMACHAL PRADESH STATE PHARMACY COUNCIL
Laureate Institute of Pharmacy, Kathog, Distt Kangra, HP - 177101
Toll Free : 18001210443 |Phone: 9218428042/9459220253|E-mail: [email protected]/[email protected]
proposed rule that would update regulatory
requirementsformostsunscreenproductsinthe
UnitedStates.
This signi�icant action is aimed at bringing
nonprescription, over-the-counter (OTC)
sunscreens that are marketed without FDA-
approvedapplicationsuptodatewiththelatest
sciencetobetterensureconsumershaveaccessto
safeandeffectivepreventativesuncareoptions.
Among its provisions, the proposal addresses
sunscreenactiveingredientsafety,dosageforms,
and sun protection factor (SPF) and broad-
spectrumrequirements.Italsoproposesupdates
tohowproductsarelabeledtomakeiteasierfor
consumerstoidentifykeyproductinformation.
SCexemptspainkillerSaridonfromthebannedlistinIndia
In a major relief for Piramal Enterprises, the
SupremeCourtexemptedpainkillerSaridonfrom
t h e l i s t o f b a nn ed FDC s ( F i xe d D o s e
Combinations)inIndia.
Thehealthministryhadbannedthemanufacture,
sale and distribution of 328 � ixed dose
combinations(FDCs)ofdrugsinSeptemberlast
year. The ban included popular drugs like
painkiller Saridon, skin cream Panderm,
combination diabetes drug Gluconorm PG,
antibioticLupidicloxandantibacterialTaximAZ.
Severalpopularcoughsyrups,painkillersandcold
medicinesarecombinationdrugs,containingtwo
ormoretherapeuticingredientsinasingledose.
Saridon is marketed by Piramal to treat
headaches. The tablet is the largest selling
painkiller in India with sales of nearly Rs 100
crore.
Ref:www.health.economictimes.indiatimes.com
MinistryofAYUSHintroducednewCentralSectorschemeforpromotingPharmacovigilanceofAYUSHDrugs
MinistryofAYUSHintroducednewcentralSector
scheme for promoting pharmacovigilance of
Ayurveda, Siddha, Unani and Homoeopathy
(ASU&H)Drugs.Primeobjectiveoftheschemeis
to develop the culture of documenting adverse
effects and undertake safety monitoring of
Ayurveda,Siddha,UnaniandHomoeopathydrugs
and surveillance of misleading advertisements
appearingintheprintandelectronicmedia.The
Standing Finance Committee (SFC) chaired by
Secretary (AYUSH) approved the schemeon1st
November,2017andthereafteritwasrolledout
forimplementationinthecountryneartheendof
�inancialyear2017-18.
Theschemeintendstofacilitatetheestablishment
o f t h r e e - t i e r n e t w o r k o f N a t i o n a l
PharmacovigilanceCentre(NPvCC),Intermediary
Pharmacovigilance Centres (IPvCCs) and
Peripheral Pharmacovigilance Centres (PPvCC).
All India Institute of Ayurveda, New Delhi, an
autonomousbodyundertheMinistryofAYUSH,
h a s b e e n d e s i g n a t e d a s N a t i o n a l
Pharmacovigilance Centre for coordinating
various activities of the initiative. In the initial
phase of implementation, �ive (05) National
Institutes of AYUSH are designated as the
Intermediary Pharmacovigilance Centres and
forty two (42) institutions of AYUSH having
6
DRUG INFORMATION CENTER HIMACHAL PRADESH STATE PHARMACY COUNCIL
Laureate Institute of Pharmacy, Kathog, Distt Kangra, HP - 177101
Toll Free : 18001210443 |Phone: 9218428042/9459220253|E-mail: [email protected]/[email protected]
clinical facilities as Peripheral Pharmacovigilance Centres to take up the work of reporting,
documentation,analysis,causalityassessmentoftheadversereactionsandeventsassociatedwiththe
consumption ofAyurveda,Unani, Siddha andHomoeopathydrugs. It is intended to havemore such
centresacrossthecountryandachievethetargetof100peripheralpharmacovigilancecentresby2020.
Ref:www.pharmatutor.org
TheU.S.FoodandDrugAdministration permittedmarketingoftheTandemDiabetesCaret:SlimX2
insulinpumpwithinteroperabletechnology(interoperablet:SlimX2)fordeliveringinsulinunderthe
skinforchildrenandadultswithdiabetes.Thisnewtypeofinsulinpump,referredtoasanalternate
controllerenabled(ACE)infusionpump,orACEinsulinpump,isthe�irstinteroperablepump,meaningit
canbeusedwithdifferentcomponentsthatmakeupdiabetestherapysystems,allowingpatientstotailor
theirdiabetesmanagement to their individualdevicepreferences.Diabetes therapy systemsmaybe
comprisedofanACEinsulinpumpandothercompatiblemedicaldevices,includingautomatedinsulin
dosing(AID)systems,continuousglucosemonitors(CGMs),bloodglucosemetersorotherelectronic
devicesusedfordiabetesmanagement.
Ref:www.pharmatutor.org
FDAauthorizes�irstinteroperableinsulinpumpintendedtoallowpatientstocustomizetreatmentthroughtheirindividualdiabetesmanagementdevices
7
DRUG INFORMATION CENTER HIMACHAL PRADESH STATE PHARMACY COUNCIL
Laureate Institute of Pharmacy, Kathog, Distt Kangra, HP - 177101
Toll Free : 18001210443 |Phone: 9218428042/9459220253|E-mail: [email protected]/[email protected]
Pharmacist Result
HimachalPradeshStaffSelectionCommissionhascompiledthe�inalresultof142postsofPharmacist
(Allopathy)(oncontractbasis)PostCode-586onthebasisofthemarksobtainedinwrittenobjectivetype
screeningtestandevaluationprocess.ThecandidatesbearingthefollowingRollNumbers have been
declaredsuccessful:-
Sr. No. Roll No. Name Total Marks
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
586000016
586000049
586000101
586000155
586000169
586000170
586000212
586000275
586000465
586000531
586000594
586000611
586000627
586000661
586000671
586000725
586000740
586000764
SUSHMA
PRATIBHAKUMARI
SUMANKUMAR
SUNILKUMAR
ANJULKUMAR
KISHORILAL
SHALINIKUMARI
NEERAJ
SANDEEPSHANDIL
KANHIEYASHARMA
ANJALISHARMA
AJAYSINGH
TILAKRAJ
DEEPIKARANI
MONIKABHARDWAJ
AMITKUMAR
50.92
46.22
55.14
56.71
54.82
46.64
46.1
52.16
46.03
43.88
50.61
46.62
46.99
53.38
50.25
45.62
52.15
49.52
ASHWANIKUMAR
RANBIRSINGH
8
DRUG INFORMATION CENTER HIMACHAL PRADESH STATE PHARMACY COUNCIL
Laureate Institute of Pharmacy, Kathog, Distt Kangra, HP - 177101
Toll Free : 18001210443 |Phone: 9218428042/9459220253|E-mail: [email protected]/[email protected]
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
AKHILESHKUMAR
ANUPRIYA
VINAYKUMAR
KARAMJEETSINGH
SWATISHARMA
CHANDERREKHA
NIKHLESHSINGH
47.57
44.45
45.22
53.7
54.42
53.58
67.02
586000786
586000986
586000997
586001058
586001081
586001083
586001092
586001123
586001177
586001274
586001283
586001288
586001352
586001355
586001521
586001539
586001542
586001627
586001661
586001663
586001686
586001695
586001728
586001785
MONIKADEVI
BOBYJASWAL
SURINDERKUMAR
KUMARIRANIDEVI
VINODKUMAR
LALITGULERIA
DIPIMACHAUDHARY
DEEPMALA
JYOTIKAUDAL
SAVITADEVI
UMESHKUMAR
DEEPSHIKHASHARMA
ANKAJKAUNDAL
REETIKADADIAL
RAGHAVDOGRA
ARCHANAKASHYAP
ANJU
53.05
46.03
55.67
43.98
46.17
61.43
48.43
48.84
44.29
44.75
45.93
53.21
50.76
47.3
53.54
44.32
46.81
9
DRUG INFORMATION CENTER HIMACHAL PRADESH STATE PHARMACY COUNCIL
Laureate Institute of Pharmacy, Kathog, Distt Kangra, HP - 177101
Toll Free : 18001210443 |Phone: 9218428042/9459220253|E-mail: [email protected]/[email protected]
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
586001811
586001821
586001823
586001883
586001908
586001918
586001936
586001955
586002028
586002067
586002122
586002138
586002152
586002198
586002281
586002283
586002345
586002347
586002350
586002508
586002617
586002671
586002920
586003013
ISHABHARTI
ANITARANI
SUDHIRKUMAR
AMANSINGH
MAMTAPALIA
SHIKHACHOUDHARY
AJAYKUMAR
SWATI
GOPAL
BHUPINDERSINGH
RAHULSHARMA
SUNNYRANA
NEHADHIMAN
SAMRIDHIBUGWAN
POOJARANI
GOVILSHARMA
KUSHMADEVI
SHAILJA
NITINDHIMAN
BALKRISHAN
RAJEEVBHARTI
TANZINDOLKER
BHIMIKUMARI
AJAYKUMAR
56.37
51.67
45.72
45.7
43.25
51.97
49.52
46.62
46.33
52.66
63.42
54.57
46.68
57.97
51.04
55.74
52.22
46.77
42.13
45.67
46.41
44.96
50.3
46.59
10
DRUG INFORMATION CENTER HIMACHAL PRADESH STATE PHARMACY COUNCIL
Laureate Institute of Pharmacy, Kathog, Distt Kangra, HP - 177101
Toll Free : 18001210443 |Phone: 9218428042/9459220253|E-mail: [email protected]/[email protected]
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
586003048
586003079
586003122
586003172
586003193
586003225
586003242
586003286
586003380
586003482
586003489
586003509
586003512
586003549
586003582
586003594
586003596
586003602
586003614
586003741
586003766
586003777
586003802
586003811
CHANDRIKAKUMARI
ANJANAKUMARI
OMPRAKASH
VINAYKUMAR
RAVISINGH
ASHOKKUMAR
LUDERMANI
CHATTARSINGH
CHATTERSINGH
NEELAMRAJ
RAKESHKUMAR
TAPENDERKUMAR
RAVIKUMAR
ANILKUMAR
VANDANASHARMA
POOJADEVI
VINAYDHATWALIA
BHIMSINGH
REENAKUMARI
BABITADEVI
PRAJJUALMAKHAIK
SOHANLAL
MANOJKUMAR
SHASHIBALA
55.56
54.49
54.79
60.04
44.75
45.76
53.4
47.35
54.17
54.77
47.8
49.94
40.92
58.15
45.26
56.35
53.92
54.47
56.03
61.37
57.42
54.01
45.93
46.75
11
DRUG INFORMATION CENTER HIMACHAL PRADESH STATE PHARMACY COUNCIL
Laureate Institute of Pharmacy, Kathog, Distt Kangra, HP - 177101
Toll Free : 18001210443 |Phone: 9218428042/9459220253|E-mail: [email protected]/[email protected]
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
586003860
586003921
586003934
586003945
586003984
586004032
586004312
586004469
586004540
586004559
586004628
586004692
586004729
586004785
586004850
586004878
586004887
586004915
586004919
586004956
586004962
586004979
586005046
586005049
ROHIT
AARTI
RAVINDERSINGH
PREETI
RUCHIMISTA
DEEPASHARMA
BALDEVSINGH
SHIVANIDEVI
KANCHANSHARMA
RAKESHKUMAR
ARCHANATHAKUR
CHETNAJHAGTA
SAMMIKUMAR
PRAMODKUMAR
RAMANKUMAR
VEENA
RUPINDERKAUR
VISHALCHAUHAN
DAISYBANSAL
DALEEPKUMAR
SANDEEPKUMAR
UDAYVEERSINGHTHAKUR
NAVEJANSARI
BHUMIKAMANGLA
46.14
56.43
56.08
54.93
41.35
57.12
45.18
46.36
52.26
60.73
54.91
53.37
56.99
46.48
42.08
47.89
44.31
52.12
52.81
45.98
47.16
55.03
56.26
58.43
12
DRUG INFORMATION CENTER HIMACHAL PRADESH STATE PHARMACY COUNCIL
Laureate Institute of Pharmacy, Kathog, Distt Kangra, HP - 177101
Toll Free : 18001210443 |Phone: 9218428042/9459220253|E-mail: [email protected]/[email protected]
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
586005210
586005247
586005373
586005414
586005433
586005440
586005476
586005532
586005669
586005720
586005795
586005821
586005916
586005969
586006000
586006017
586006020
586006083
586006322
586006367
586006386
586006416
586006469
586006562
586006630
BINDIA
CHIRAG
MEENADEVI
MANJEETSINGH
RANJANATHAKUR
SHIVANI
RUCHIKASHARMA
POONAMJINTA
DINESHKUMAR
NITIKAKASHYAP
NEHA
RAJESHKUMAR
NISHA
PREETI
POONAMNEGI
JYOTI
VEENITKUMAR
RAJATKUMAR
POOJARANI
INDUBALA
AKANKSHARATTAN
MOHAMMADTAHIR
NIKITADEVI
POONAMKUMARI
SANDEEPSINGH
47.33
62.54
63.75
49.97
52.36
54.72
46.3
51.75
41.28
50.86
48.4
46.07
55.99
53.85
48.44
43.97
53.42
49.1
48.87
44.81
47.77
48.26
45.62
55.82
44.58
13
DRUG INFORMATION CENTER HIMACHAL PRADESH STATE PHARMACY COUNCIL
Laureate Institute of Pharmacy, Kathog, Distt Kangra, HP - 177101
Toll Free : 18001210443 |Phone: 9218428042/9459220253|E-mail: [email protected]/[email protected]
Total:139Candidates.
03posts{OBC(WFF)=02&SC(WFF)=01}categoryhavebeenremainedvacantduetononavailability
ofcandidates.
Theresultisalsoavailableontheof�icialwebsiteoftheHPSSC,Hamirpur.(http://www.hpsssb.hp.gov.in).
Noble Prize in Physiology or Medicine, 2018
The2018NobelPrizeinPhysiologyorMedicinewasawardedtoJamesP.AllisonandTasukuHonjofor
discoveriesthathaveledtonewmedicinesthatactivatetheimmunesystemanddriveitto�ightcancers.
Thesetherapiescandefeateventhedeadliestmalignancies.Todate,ourbest tools for treatingaggressivecancers thathavespreadbeyondtherangeofcurative
surgeryhavebeenradiationtherapyandsystemicchemotherapyagents.Tounderstandthesigni�icance
ofAllisonandHonjo’sdiscoveries,onemustappreciateresearchershavebeentryingtorallyapowerful
immuneresponseagainsttumorcellsforthepastcentury.PriortoAllisonandHonjo’swork,researchers
believed that aggressive cancers grewunchecked because the immune responsewas tooweak. The
consensuswasthatifonecouldstimulatetheimmunesystem,itwouldrespondanddestroytheinvasive
tumorcells.AllisonandHonjo,however,madeacriticalleapwhentheycharacterizedtwoveryimportant
andpotentpathways–called“immunecheckpoints”–thatcanshutdowntheimmuneresponse.These
pathways inhibitTcells–whitebloodcells thatarechargedwithdestroyingvirus-infectedcellsand
tumorcells–andpreventthemfrom“seeing”andattackingthetumor.AllisonandHonjoidenti�iedand
characterizedtwodifferentproteins,calledCTLA-4andPD-1,respectively,thatsitonthesurfaceofT-
cells.Whentheseproteinsinteractwithmatchingproteinsontumorcellsorotherimmunecells–theway
akey�itsalock–theT-cellsfallinto“sleepmode”anddon’tattackthetumor.Inmanypatientswithcancer,theseCTLA-4andPD-1pathwaysshutdownanti-tumorimmuneactivity.
Withoutimmunesurveillance,thetumorsgrowandspread.Thismeantthatourearlyattemptstoactivate
14
DRUG INFORMATION CENTER HIMACHAL PRADESH STATE PHARMACY COUNCIL
Laureate Institute of Pharmacy, Kathog, Distt Kangra, HP - 177101
Toll Free : 18001210443 |Phone: 9218428042/9459220253|E-mail: [email protected]/[email protected]
theimmunesystemwereliketryingtodriveacarwiththebrakepedalpressedtothe�loor.Nomatterhow
wetried,orsteppedonthegas,thebrakesthwartedanyprogress.ButAllisonandHonjo’sresearchledto
the development of a new type of drug:monoclonal antibodies that block the regulatory pathways
controlledbyCTLA-4andPD-1.Thesedrugs,calledimmunecheckpointinhibitors,basicallyattachtothe
CTLA-4andPD-1proteinsandpreventthemfromswitchingofftheT-cells.Thesenewantibody-drugs
haveledtodramatictumorregressions.TheresultsaresoimpressivethattheFDAhasapprovedtheiruse
foravarietyof advancedcancers suchas:metastaticmelanoma, lungcancer,kidneycancer,bladder
cancer,headandneckcancers,andothertumors.
Ref:www.google.com
Local News
Ref: Amar Ujala, 14-02-2019
15
DRUG INFORMATION CENTER HIMACHAL PRADESH STATE PHARMACY COUNCIL
Laureate Institute of Pharmacy, Kathog, Distt Kangra, HP - 177101
Toll Free : 18001210443 |Phone: 9218428042/9459220253|E-mail: [email protected]/[email protected]
Ref:AmarUjala,20-02-2019
Ref:AmarUjala,28-02-2019
TollFree18001210443
ScanthisQuickResponse(QR)
codetoknowmore
YoumaydownloadanyQRcodescannerfrom
PlayStore/iTunes
HIMACHALPRADESHSTATE PHARMACYCOUNCIL
DRUGINFORMATIONCENTER
LaureateInstituteofPharmacy,Kathog,Distt.Kangra,HP-177101
TollFree:18001210443|Phone:09218428042/9459220253
E-mail:[email protected]/[email protected]
TollFree:18001210443|Phone:9218428042/9459220253
Foranyclari�ications,anyonecandirectlycalltotheDICof�iceorsendtheirquerybypost
orE-mailtothebelowaddress.
Note:Ifanyonewanttopublishhis/herarticleinthemonthlybulletinofDrug InformationCenterregardingPharmaupdates, theycansend theirarticleswith their full address and professional status on the followingreferencebefore25��ofeverymonth.
© 2
019 P
harm
a P
uls
e | in
fo@
pharm
apuls
e.in
| 9
482797901